GLP-1 drugs are driving higher sales for Eli Lilly and Novo Nordisk - National
Reuters reports that GLP-1 demand boosted quarterly results and raised full-year revenue guidance for Eli Lilly. Mounjaro Q2 sales rose 91% to $9.94B and Zepbound rose to $4.93B. Novo Nordisk said Wegovy oral met expectations; operating profit rose 11% and U.S. prescriptions surpassed 5M. Both cited Canada generic competition.
How this was made
The 30-second read
Why it matters
For traders, the key actionable items are Lilly’s raised full-year revenue forecast and the magnitude of Mounjaro and Zepbound sales, plus Novo Nordisk’s operating profit growth and Wegovy oral prescription milestone amid mixed investor sentiment.
Market read
GLP-1 leaders delivered strong reported sales and guidance (Lilly) and resilient profitability with oral momentum (Novo), while generics and oral demand softness remain key swing factors.
What to watch
The article flags supply constraints among generic players, which may temporarily protect brand volumes; if constraints ease, future read-through could weaken.
Background
The piece frames both Eli Lilly and Novo Nordisk as benefiting from GLP-1 popularity, while also addressing early generic competition in Canada and the shift toward oral formulations.
Ticker impact
Eli Lilly reported Q2 sales for Mounjaro up 91% to $9.94B and raised its full-year revenue forecast, with shares up 2.5%.
Bullish bias for the next few sessions, with follow-through tied to continued guidance confidence.
The article cites specific Q2 sales beats, a full-year forecast raise, and a same-day stock move, all directly tied to LLY’s GLP-1 franchise.
Novo Nordisk said operating profit rose 11% and Wegovy oral sales surpassed five million U.S. prescriptions since launch, despite some “soft” commentary.
Moderate, range-bound reaction risk unless management commentary on oral demand translates into stronger forward growth.
The article provides profit and prescription milestones, but notes analysts found Wegovy sales “slightly soft,” creating mixed read-through.
Market effects
Reinforces GLP-1 category strength while highlighting competitive pressure from generics and the importance of volume retention strategies.
Growth is described as strong in the U.S. and accelerating internationally for Lilly, with Canada specifically discussed for retention amid generics.
Signals continued global demand for GLP-1 therapies and ongoing competitive dynamics between leading brands and generic entrants.
Counterpoint
Generics are already capturing share in Canada, and “slightly soft” Wegovy oral demand could indicate growth is normalizing rather than accelerating.
Key entities
- companyEli Lilly
Reported Q2 GLP-1 sales growth, better-than-expected quarterly results, and raised full-year revenue forecast.
- companyNovo Nordisk
Reported operating profit growth and Wegovy oral prescription milestone, while addressing investor concerns about oral sales strength.
- executiveLucas Montarce
Lilly CFO cited U.S. and international revenue growth drivers on an earnings call.
- executiveMike Doustdar
Novo Nordisk CEO discussed increased obesity treatment reach and oral demand interest.
- executiveEmil Kongshøj Larsen
Novo Nordisk executive described Canada savings-card strategy and volume retention amid generics.
